Abstract:Osteosarcoma is the most common malignant bone tumor in children. Despite the use of chemotherapy and surgery, the survival of patients with metastasis is still dismal. We have previously reported that a high serum level of CXCL10 is associated with a poor prognosis and metastasis in osteosarcoma, suggesting that the chemokine may affect the development of metastasis. Nonetheless, the effect of endocrine signaling of CXCL10 is largely unknown. It is unclear if the prognostic effect of circulating CXCL10 is due to its metastasis-promoting effect or if CXCL10 is merely a biomarker. In this study, we employed orthotopic xenograft mouse models to examine the effect of circulating CXCL10 with respect to metastasis. We first injected luciferase-labeled 143B osteosarcoma cells into the tibia of NOD/SCID mice to generate an orthotopic xenograft mouse model. When the tumor was detectable by bioluminescence, we injected 1.5ug of CXCL10 protein or saline intravenously via the tail vein every day for two weeks. The development of pulmonary metastasis was monitored by bioluminescence. The mice were sacrificed at the endpoint when bioluminescence was detected in the lungs. The mouse lungs were then resected and examined by H&E staining for the detection of metastatic nodules. The mice in the experimental and control groups that developed lung metastases were compared. The results showed that no significant difference was observed between the two groups. The experiment was repeated one more time and similar results were observed. To investigate the influence of the cell line background, we analyzed another osteosarcoma cell line, MG63.3. No significant difference in metastasis development was observed between the mice injected with CXCL10 and the mice injected with saline. The results indicate that a higher level of circulating CXCL10 alone was not sufficient to promote pulmonary metastases in the orthotopic xenograft mouse models. We also showed that AKT phosphorylation was upregulated in the osteosarcoma cell lines incubated with CXCL10, ruling out that the CXCL10 protein used was biologically inactive. In summary, our results suggest that although an increased circulating level of CXCL10 is associated with a poor prognosis in osteosarcoma patients, it does not promote the development of pulmonary metastasis in xenograft mouse models. Circulating CXCL10 may only act as a prognostic biomarker, but not a metastatic driver. Alternatively, the CXCL10-CXCR3 axis may be necessary, but not sufficient, to cause metastasis. Citation Format: Xiang Chen, Margaret Clement, John Hicks, Tsz Kwong Man. The effect of circulating CXCL10 on osteosarcoma metastasis using orthotopic xenograft mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited s); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl) nr 1307.

Interleukin-6 Suppression Reduces Tumour Self-Seeding By Circulating Tumour Cells In A Human Osteosarcoma Nude Mouse Model

AASLD Abstracts 220-442

Mesenchymal Stem Cells-Derived IL-6 Promotes Invasion and Metastasis of Oral Squamous Cell Carcinoma Via JAK-STAT3 Signalling

IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung

Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway

Effects of Interleukin-6 on STAT3-regulated signaling in oral cancer and as a prognosticator of patient survival

Interleukin-6 signaling pathway in targeted therapy for cancer.

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Interleukin-6 Enhances Cancer Stemness and Promotes Metastasis of Hepatocellular Carcinoma Via Up-Regulating Osteopontin Expression.

Human Mesenchymal Stem Cells Promote Growth of Osteosarcoma: Involvement of Interleukin‐6 in the Interaction Between Human Mesenchymal Stem Cells and Saos‐2

IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment

IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma

NEK6 Promotes the Progression of Osteosarcoma Through Activating STAT3 Signaling Pathway by Down-Regulation of Mir-26A-5p

IL‑6 Plays a Crucial Role in Epithelial‑mesenchymal Transition and Pro‑metastasis Induced by Sorafenib in Liver Cancer.

The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells

Supplementary Data from IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung

Interleukin-6 Promotes Tumor Progression in Colitis-Associated Colorectal Cancer Through HIF-1α Regulation

Abstract 1307: The effect of circulating CXCL10 on osteosarcoma metastasis using orthotopic xenograft mouse models

IL-6 Promotes the Proliferation and Immunosuppressive Function of Myeloid-Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer

STAT3 Activation by IL-6 from Mesenchymal Stem Cells Promotes the Proliferation and Metastasis of Osteosarcoma.